Form 8-K

8-K — Niki BioSolutions, Inc.

Accession: 0001213900-26-109016

Filed: 2026-10-13

Period: 2026-10-13

CIK: 0001734005

SIC: 3829 (MEASURING & CONTROLLING DEVICES, NEC)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — ea0308307-8k_niki.htm (Primary)

EX-10.1 — EMPLOYMENT AGREEMENT WITH THOMAS FREEBURG (ea030830701ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0308307-8k_niki.htm · Sequence: 1

false

0001734005

2026-10-13

0001734005

dei:FormerAddressMember

2026-10-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 13, 2026

Niki

BioSolutions, Inc.

(Exact

name of Registrant as Specified in Its Charter)

Delaware

001-38764

42-3265309

(State

or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

116

Village Boulevard, Suite 200, Princeton, NJ 08540

(Address

of Principal Executive Offices, including zip code)

Registrant’s

Telephone Number, Including Area Code: 609-951-2222

Aptorum

Group Limited

Hanover Square

London

W1S 1BN, United Kingdom

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common

stock, par value $0.0001 per share

NIKI

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”),

appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing

as of September 1, 2026, unless terminated sooner by either party.

Prior

to his appointment, Mr. Freeburg, age 59, was the Managing Member of Cambridge Accounting Group, LLC from 2014 to September 2017 and

April 2023 to August 2026. Mr. Freeburg was previously employed by Interpace Biosciences, Inc. (NASDAQ: IDXG) and served as the company’s

Chief Accounting Officer from October 2017 through January 2021, and as Chief Financial Officer, Secretary and Treasurer from February

2021 through March 2023. From 2009 to 2014, Mr. Freeburg served as the Director of SEC Reporting and Accounting Policies for Coach, Inc.,

which was the predecessor company to Tapestry, Inc. (NYSE: TPR). From 2006 to 2008, Mr. Freeburg served as the Director of External Reporting

of Scholastic Corporation (NASDAQ: SCHL). Mr. Freeburg is a Certified Public Accountant and earned his Bachelor of Science degree in

Public Accounting from Long Island University.

Pursuant

to the terms of the Employment Agreement between the Company and Mr. Freeburg, Mr. Freeburg will receive a base salary of $250,000, which

shall be paid monthly although $25,000 shall be deferred until such time as the Company receives certain funding, as set forth in the

Employment Agreement; his base salary shall increase to $275,000, upon the Company’s receipt of additional funding. Mr. Freeburg

is also entitled to an annual bonus in an amount up to 50% of his base salary. Mr. Freeburg shall also receive 50,000 stock options,

with an exercise price equal to $8.83 per share, with an agreed upon vesting schedule. Either party can terminate the agreement upon

45 days’ notice prior to the end of the then current term, and the Company may remove Mr. Freeburg at any time for cause and to the extent

permitted by applicable law; the Employment Agreement specifies the benefits and compensation for which Mr. Freeburg is entitled based

upon the reason for such termination. Mr. Freeburg is also entitled to specified benefits and severance payments.

There

are no family relationships between Mr. Freeburg and any director or executive officer of the Company, and there are no arrangements

or understandings between Mr. Freeburg and any other person pursuant to which he was selected as an officer of the Company. Mr. Freeburg

has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The

foregoing summary of the Employment Agreement is qualified in its entirety by reference to said agreement, which is filed as Exhibit

10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Description

10.1

Employment Agreement with Thomas Freeburg

104

Cover

Page Interactive Data File, formatted in Inline XBRL

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Dated:

October 13, 2026

NIKI BIOSOLUTIONS, INC.

By:

/s/

Ian Huen

Ian

Huen

Chief

Executive Officer

EX-10.1 — EMPLOYMENT AGREEMENT WITH THOMAS FREEBURG

EX-10.1

Filename: ea030830701ex10-1.htm · Sequence: 2

Exhibit 10.1

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”),

is made by and between Niki BioSolutions, Inc., a Delaware corporation, (the “Company”) whose mailing address

is 116 Village Boulevard, Suite 200, Princeton, NJ 08540 and Thomas Freeburg (the “Executive”), residing at

XXX. Executive and Company are hereinunder sometimes referred to individually as a “Party” and collectively as “Parties.”

WHEREAS, the Company desires

to employ Executive and to have the benefit of his skills and services under the terms of this Agreement, commencing on September 1, 2026

(the “Commencement Date”) upon and subject to the terms herein provided; and

WHEREAS, Executive is willing

to agree to be employed by the Company upon and subject to the terms herein provided;

NOW, THEREFORE, in

consideration of the mutual promises, terms, covenants and conditions set forth herein and in the Non-Disclosure, Non-Solicitation, and

Intellectual Property Assignment Agreement (“Non-Disclosure and IP Assignment Agreement”), attached as Exhibit A and

hereinafter defined, and the performance of each, the parties hereto, intending legally to be bound, hereby agree as follows:

1. Prior

Agreements, Acknowledgment and Release. As of the Commencement Date all prior consulting agreements and any amendments thereto,

whether with DiamiR, the Company, Aptorum Group Limited, a Cayman Islands exempted company with limited liability, or any other entity

affiliated with the Company, are terminated, except for those terms that are intended to survive termination.

2. Position.

The terms of Executive’s position with the Company are as set forth below:

(a) Title and Reporting - Executive shall serve as Chief Financial Officer of the Company, and shall have responsibilities, duties and authority normally ascribed to that position in a life sciences company of similar size and stage in the biotechnology industry as assigned to Executive from time to time by the Chief Executive Officer (“CEO”) and/or the Board of the Company (the “Board”).

(b) Duties - The Executive shall have overall responsibility for the Company’s day-to-day financial operations of the Company including, but not limited to, leading the Company’s overall financial strategy, planning, execution, and advising the CEO and Board on:

● Capital allocation and growth strategy;

● Financial risks and opportunities;

● Developing and maintaining long-term financial models and forecasts;

● Overseeing budgeting, forecasting, and financial planning processes;

● Oversight and certification of all filings with the U.S. Securities and Exchange Commission, including

Form 10-K, Form 10-Q, Form 8-K, and Proxy statements (DEF 14A);

● Ensuring compliance with the Sarbanes-Oxley Act (SOX), GAAP and applicable accounting standards;

● Establishing and maintaining disclosure controls and procedures;

● Overseeing Information technology general controls regarding financially relevant systems;

● Coordinating external auditors and managing annual audits;

● Overseeing all tax matters, including federal, state, and international tax compliance and tax planning

and optimization; and

● Managing relationships with external tax advisors.

(c) Executive shall act at all times to promote the Company’s business and best interests. Executive shall devote substantially all of his business time and attention, labor, skill and best ability to the performance of his duties hereunder in a manner and effort to, faithfully and diligently further and expand the business and interests of the Company.

(d) The CEO and Board will evaluate Employee annually, and Executive will be required to perform self-evaluation annually.

(e) Executive will consult with the CEO and the Board prior to accepting any other (or further) directorships of companies or any external appointments and promptly inform the Board of acceptance of any such appointment. All potential conflicts of interest must be disclosed, as specified under the Company’s Conflicts policy.

3. Employment

Term. Unless the Executive’s employment shall sooner terminate pursuant to Section “4,” the Company shall employ

the Executive for a term of two years commencing on the Commencement Date (the “Initial Term”). Following the Initial Term,

this Agreement shall automatically renew for successive one (1) year terms (the “Term”) unless either party provides written

notice at least 45 (forty-five) days prior to the end of the then current Term that it will not be renewing the Agreement.

4. Termination.

(a) Accrued

Obligations. Upon the termination of Executive’s employment with the Company for any reason, Executive shall be entitled to

receive (i) any Base Salary that had accrued but had not been paid through the termination date; (ii) all accrued and unused PTO time;

and (iii) any reimbursement due to Executive pursuant to Section 6(c) (collectively, the “Accrued Obligations”).

(b) Involuntary

Termination. If Executive’s employment is terminated by the Company without Cause (as defined herein) or if Executive resigns

from Executive’s employment for Good Reason (as defined herein) (for purposes of clarity, a termination without Cause does not include

a termination that occurs as a result of Executive’s death or disability), and provided that such termination constitutes a “separation

from service” as defined in Treasury Regulation Section 1.409A-1(h) (“Separation”) and Executive timely signs and does

not revoke a general release ( “Release”) of all claims, including employment claims (the “Deadline” or the “Effective

Date”), then in addition to the Accrued Obligations, Employee shall be paid within 10 (ten) days of the Effective Date in a single

lump sum payment if the termination is during the Initial Term, the remaining balance of his then current Base Salary through the end

of the Initial Term or six (6) months, whichever is greater (“Severance Pay”). As a condition of receiving Severance

Pay, Executive must, within five business days after Executive’s employment terminates for any reason, deliver written resignation(s)

effective immediately upon delivery, from any and all positions and offices he holds with Employer or any of its affiliates, or any board

of directors thereof.

for Cause. If Executive’s employment with the Company terminates for Cause by the Company or due to Executive’s death

or Total Disability, then all payments of compensation by the Company to Executive hereunder will terminate immediately (except Accrued

Obligations). For purposes hereof, Executive shall be deemed to experience a Total Disability if he shall have been unable to perform

his duties hereunder on a full-time basis for 60 consecutive days or longer, or for shorter periods aggregating 90 days in any 360-day

period. Upon termination of the Executive’s employment for Cause, the Executive shall be entitled only to:

(i) earned but unpaid Base Salary through

the date of termination;

(ii) reimbursement of properly incurred business

expenses in accordance with Company policy;

(iii) vested benefits under any applicable

employee benefit plans in accordance with the terms of such plans; and

(iv) any other amounts required by applicable

law.

Except as otherwise expressly provided in any applicable

equity award agreement or equity incentive plan, all unvested equity awards shall be immediately forfeited upon a termination for Cause,

and any post-termination exercise rights shall be governed by the applicable equity award agreements and the Company’s equity incentive

plan.

(d) Voluntary

Termination. Executive may terminate his employment without Good Reason upon 45 days written notice, in which case and provided that

such termination constitutes a “separation from service” as defined in Treasury Regulation Section 1.409A-1(h) (“Separation”)

and Executive signs and does not revoke a general Release and such Release becomes effective within thirty (30) days of Executive’s

Separation (the “Deadline”), Executive (or his estate or representative, as applicable) shall be paid the Accrued Obligations.

(e) Expiration

of Term. Termination of this Agreement due to expiration of the Initial Term, or of any subsequent term, due to non-renewal, shall

not be considered a termination without “Cause” or a resignation for “Good Reason,” and shall entitle the Executive

to Severance Pay in a single lump sum payment equal to three months of his then current Base Salary.

(f) Forfeiture

of Rights. In the event that, subsequent to termination of Executive’s employment hereunder, Executive materially breaches any

provision of the Non-Disclosure and IP Assignment Agreement, the Company shall provide written notice to Executive specifying in reasonable

detail the nature of such alleged breach. Executive shall have thirty (30) days following receipt of such notice to cure such breach,

to the extent curable. If Executive fails to cure such breach within such thirty (30)-day period (the “cure period”) or if

the breach is not curable as agreed to by a majority of the independent board members, the Company may, as its sole and exclusive remedy

with respect to such breach, suspend and thereafter terminate any unpaid payments and benefits to which Executive would otherwise be entitled

pursuant to this Section 4; provided, however, that (i) any payments already received by Executive prior to such suspension shall not

be subject to clawback or repayment, (ii) such forfeiture shall apply only to payments and benefits arising under this Section 4 and shall

not affect any vested equity, accrued but unpaid base salary, or vested retirement benefits, and (iii) the Company’s right to forfeiture

shall be subject to a final determination by a court of competent jurisdiction if Employee disputes the existence or materiality of such

breach within thirty (30) days after the cure period.

5. Definitions.

(a) Cause. For purposes of this Agreement, “Cause” is defined as

(i) Executive’s willful fraud upon, or deliberate injury or attempted injury to, the Company;

(ii) Executive’s gross negligence or intentional misconduct with respect to the performance of Executive’s

duties under this Agreement or any contract between Executive and the Company after written notice from the Board specifying such failure

and the Executive’s failure to cure within thirty (30) days.

(iii) conduct of Executive that, based upon a good faith and reasonable factual investigation and determination

by the Board, demonstrates Executive’s gross unfitness to serve, including continued or excessive absences or tardiness (not including

authorized leaves or absence, FMLA leave, or absences that are a result of an accommodation under ADA);

(iv) Executive’s material breach of: (x) this Agreement or the Non-Disclosure and IP Assignment Agreement

or (y) any statutory (including fiduciary) duty of the Executive to the Company; provided, however, that no such termination under this

subsection (iv) or (ii) above will be deemed to be a Termination for Cause unless the Company has provided Executive with written notice

of what it reasonably believes are the grounds for any Termination for Cause and Executive fails to take appropriate remedial actions

within thirty (30) day period following receipt of such written notice.

(v) Notice and Opportunity to Cure. Except in the case of fraud, embezzlement, theft, or other

conduct that is not reasonably capable of cure, the Company shall provide the Executive with written notice describing the alleged grounds

for Cause in reasonable detail. The Executive shall have thirty (30) days following receipt of such notice to cure the alleged conduct,

if curable.

(vi) Board Determination. A termination for Cause shall become effective only upon the affirmative and

good faith approval of a majority of the Board after the Executive has been given a reasonable opportunity to present the Executive’s

position to the Board.

(b) Good

Reason. For purposes of this Agreement, “Good Reason” is defined as a voluntary resignation by Executive upon forty-five

(45) days prior written notice to the Company, within sixty (60) days following the occurrence of one or more of the following events

without Executive’s prior written consent:

(i) a reduction of Executive’s Base Salary other than as a part of an across-the-board salary reduction

of the same percentage applicable to executive officers of the Company;

(ii) removal of the Executive from the position of Chief Financial Officer (except for (i) promotion to an

equivalent or higher position or (ii) the end of the Term in accordance with Section 3) or assignment of a title or responsibilities that

are materially inferior in status, authority, or responsibility;

(iii) a material reduction in the personnel, facilities, systems, or financial resources reasonably necessary

for the Executive to perform the Executive’s duties, after written notice to the Company and a reasonable opportunity to cure;

(iv) a material breach by the Company of this Agreement; and provided further that the Company shall have thirty

(30) days after delivery of such notice to cure one or more of the foregoing events identified in such written notice, and only if the

breach is capable of cure and the Company does not cure within that time shall there be Good Reason; or

For the avoidance of doubt, nothing in this

Section shall limit or impair the Board’s fiduciary duties, oversight responsibilities, or authority under applicable law, including

but not limited to the Company’s bylaws.

6. Compensation. In consideration of the services to be rendered hereunder, the Company hereby agrees to pay Executive the compensation as set forth herein.

(a) Base

Salary. Executive will be paid an initial annual base salary (“Base Salary”) of $250,000.00 (Two Hundred Fifty Thousand

Dollars) which will be paid monthly, in accordance with the Company’s regular payroll practices, starting on Commencement Date.

$25,000 of the salary will be deferred and in the event the Company’s receives, during Executive’s Employment, an equity investment,

convertible loan, or other financial transaction, or any combination thereof (“Capital Investment”) that results in

cumulative gross proceeds to the Company during Executive’s employment of $3,000,000 (Three Million Dollars), the Company will pay

the deferred salary in whole, minus customary payroll and tax withholdings. If the Company receives a Capital Investment that results

in cumulative gross proceeds to the Company of $5,000,000 (Five Million Dollars) in cumulative gross proceeds during Executive’s

employment, the Company will increase the Executive’s Base Salary to $275,000 (Two Hundred Seventy-Five Thousand Dollars). For the

avoidance of doubt, the definition of Capital Investments includes:

a. Sales of the Company’s common stock, preferred stock, or other equity securities;

b. Private placements, public offerings, registered direct offerings, at-the-market (“ATM”) offerings,

PIPE financings, and rights offerings

c. Investments by venture capital firms, private equity funds, strategic investors, family offices, institutional

investors, or individual accredited investors

d. Convertible notes, convertible preferred stock, SAFEs, warrants, or other equity-linked financing instruments

e. Any other transaction through which the Company receives cash or other financial resources to fund its

operations or business activities.

The Base Salary may be increased, but shall not be

decreased, without the Executive’s prior written consent.

(b) Performance

Bonuses. In addition to the Base Salary, Executive shall be eligible to receive an annual bonus (the “Bonus”) in

such amounts up to 50% (fifty percent) of Base Salary, as shall be determined in the sole discretion of the Board of the Company

following the end of each fiscal.

Options. In addition to (and not in lieu of) the Base Salary and any Bonus, Executive shall, on the Commencement Date, receive a grant

of stock options (the “Option”) described in Exhibit “B” hereto. The Option shall be governed by the Niki

BioSolutions, Inc. 2026 Equity Incentive Plan (the “Plan”), subject to any specific terms set forth in Exhibit B.

7. SEVERANCE COMPENSATION. In the event of a Qualifying Termination (as defined below) and subject to the Executive’s timely execution and non-revocation of the Release within the period specified by the Company, which shall not exceed sixty (60) days following the date of termination, the Company shall provide the following severance benefits (collectively, “Standard Severance”):

(i) The Company shall pay the Executive’s Base Salary in

effect immediately before the Qualifying Termination (without regard to any reduction constituting Good Reason) in accordance with section

4(b), payable in a lump sum in accordance with the Company’s regular payroll practices, subject to applicable tax withholding;

(ii) COBRA Continuation. To the extent the Executive timely elects

continuation coverage under COBRA, the Company shall pay or reimburse the Executive for, the employer and employee portion of the COBRA

premiums for the Executive and the Executive’s eligible dependents for the duration of the Severance Period, or until the Executive

becomes eligible for comparable coverage through another employer, whichever occurs first;

(iii) Equity Acceleration. All outstanding unvested Options held

by the Executive shall immediately vest and become fully exercisable as of the effective date of the Executive’s Involuntary Termination,

subject to the terms of the applicable Equity Incentive Plan and the applicable Award Agreements; all outstanding unvested stock options

and other equity awards shall immediately vest. The Executive shall also receive:

(g) accrued but unpaid Base Salary;

(h) accrued but unused PTO payable under Company policy;

(i) reimbursement of approved business expenses;

(j) vested benefits under employee benefit plans.

(iv) A “Qualifying Termination” means a termination

of the Executive’s employment by the Company without Cause or a resignation by the Executive for Good Reason, in each case constituting

a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h) other than as a result of death,

Disability, or voluntary resignation without Good Reason.

8. Benefits.

(a) Benefit Plan – Health Insurance, Life Insurance, Retirement. Executive will be eligible to

participate in the all fringe benefits offered by the Company on the same terms and conditions as other similarly-situated employees.

The Executive may elect to waive enrollment in the Company’s group health plan, in which case the Company shall pay the Executive

a taxable monthly medical reimbursement of Five Hundred Dollars ($500). The Company reserves the right to amend, modify, or terminate

any employee benefit plan at any time in accordance with applicable law.

(b) Retirement Benefits. The Executive shall be eligible to participate in the Company’s

401(k) retirement savings plan, subject to the terms of the applicable plan documents.

Vacation may not be taken before it is accrued during the current year. Executive shall coordinate his vacation plans with the Board or

its designee, so as not to endanger important projects, deliverables and deadlines of the Company.

(d) Directors’ and Officers’ Insurance and Indemnification. During the Executive’s

employment and for so long thereafter as the Executive may remain subject to potential liability arising from the Executive’s service

to the Company, the Company shall maintain directors’ and officers’ liability insurance covering the Executive on terms and

in amounts no less favorable than those provided to other senior executive officers and directors of the Company. The Executive shall

also be entitled to the full benefit of any indemnification rights provided under the Company’s Certificate of Incorporation, Bylaws,

indemnification agreements, or applicable law.

(e) Technology Allowance. The Company

shall provide the Executive with a taxable monthly technology allowance of One Hundred Fifty Dollars ($150) to offset the cost of mobile

telephone service, internet connectivity, and other business-related communication expenses. The allowance shall be paid through the

Company’s regular business expenses process and shall not be subject to applicable tax withholding.

(f) Other Benefits. Expenses. The Company will provide Executive with standard business reimbursements

subject to Company policies and procedures and with appropriate receipts.

9. Legal

Employment, Non-Disclosure and IP Assignment Agreement. Executive’s acceptance of this offer and commencement of employment

with the Company is contingent upon the execution, and delivery to an officer of the Company, of the Company’s Non-Disclosure and

IP Assignment Agreement, a copy of which is annexed as Exhibit A for Executive’s review and execution, prior to or on Executive’s

Commencement Date. This offer is further contingent upon the fact that Executive has proof that he is legally able to work in the United

States.

10. Non-Solicitation.

Executive agrees to the non-solicitation terms set forth in the Non-Disclosure Agreement.

11. Arbitration.

This Agreement shall be governed by, construed and enforced in accordance with the law of the State of Delaware. Any controversy or claim

arising out of or relating to this Agreement, or breach of this Agreement is to be settled by arbitration in Delaware in accordance with

the Employment Arbitration Rules of the American Arbitration Association, and judgment on the award rendered by the arbitrators may be

entered in any court having jurisdiction. The provisions of this Section 10 shall specifically survive the termination of this Agreement.

12. Miscellaneous.

(a) This Agreement, together with the Schedules and Non-Disclosure

Agreement, sets forth the terms of Executive’s employment with the Company and supersedes any prior representations or agreements,

whether written or oral. This Agreement may not be modified, amended and no provision may be waived, except by a written agreement, signed

by the Company and by Executive

(a) Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective

and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect

under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will be lessened or reduced to the

extent possible or will be severed and will not affect any other provision and this Agreement will be reformed, construed and enforced

in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

(b) This Agreement will be governed by Delaware law without reference

to rules of conflicts of laws.

will not operate or be construed as a waiver of any subsequent breach of the same or other provision of this Agreement.

(d) This Agreement will be binding on, and inure to the benefit

of, the executors, administrators, heirs, successors, and assigns of the parties; provided, however, that except as expressly provided

in this Agreement, this Agreement may not be assigned either by Company or by Executive.

(e) This Agreement may be executed in several original or facsimile

or digital copy counterparts and all so executed and transmitted will constitute one Agreement, binding on all the parties hereto even

though all the parties are not signatories to the original or the same counterpart. Facsimile or digitally transmitted signatures will

be deemed valid as though they were originals and the parties may perform any and all obligations and duties in reliance on the facsimile

copies.

13. No

Inconsistent Obligations. Executive is aware of no obligations, legal or otherwise, inconsistent with the terms of this Agreement

or with his undertaking employment with the Company. The Executive represents and warrants that the execution of this Agreement by him

and his performance of his obligations hereunder will not conflict with, result in the breach of any provision of or the termination of

or constitute a default under any agreement to which the Executive is a party or by which the Executive is or may be bound. Executive

will not disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others.

14. Survival.

The provisions of this Agreement containing express survival clauses as well as the provisions of this Agreement which are intended to

apply, operate or have effect after the expiration or termination of the term of this Agreement, or at a time when the term of this Agreement

may have expired or terminated, shall survive the expiration or termination of the term of this Agreement for any reason.

15. Assistance

in Litigation. Executive shall, during and after termination of employment, upon reasonable notice, furnish such information and

proper assistance to the Company as may reasonably be required by the Company in connection with any litigation in which it or any of

its subsidiaries or affiliates is, or may become a party; provided, however, that such assistance following termination shall be furnished

at mutually agreeable times and for mutually agreeable compensation.

16. Notices.

All notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given (i) on the

date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service, or (iii)

upon confirmation of delivery when directed to the electronic mail address set forth below, if sent by electronic mail:

If to the Company:

Niki BioSolutions, Inc.

Attn: Ian Huen

116 Village Boulevard, Suite 200

Princeton, New Jersey 08540

Email: ian.huen@aptorumgroup.com

If to Executive:

Thomas Freeburg

Email:

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties

hereto have executed this Employment Agreement as of the date first written above.

EXECUTIVE

Niki biosolutions, inc.

By:

Thomas Freeburg

Print Name:

Ian Huen

Print Title:

Chief Executive Officer

EXHIBIT A

NON-DISCLOSURE, NON-SOLICITATION, AND

INTELLECTURAL PROPERTY ASSIGNMENT AGREEMENT

This Non-Disclosure, Non-Solicitation and Intellectual

Property Assignment Agreement (this “Agreement”), dated as of September 1, 2026, is made by and between Niki BioSolutions,

Inc., a Delaware corporation (the “Company”) whose mailing address is 116 Village Boulevard, Princeton, New Jersey

08540 and Thomas Freeburg (the “Employee”), residing at XX.

WHEREAS, Employee is commencing employment

with the Company pursuant to that certain Employment Agreement executed by and between the Company and Employee on the date thereof (the

“Employment Agreement”). Any terms not otherwise defined herein, shall have the meaning set forth in the Employment Agreement;

WHEREAS, the Company wishes to enter into this

Non-Disclosure, Non-Solicitation and Intellectual Property Assignment Agreement (this “Agreement”) with Employee to protect

the Company’s competitive position and to ensure the continued ownership and protection of the confidential and proprietary information

of the Company and others with whom the Company does business and to avoid the solicitation by Employee of the Company’s customers,

collaborators and other employees;

WHEREAS, Employee recognizes the Company’s

need for this Agreement to protect the Company’s competitive position and to ensure the continued ownership and protection of the

confidential and proprietary information of the Company, its Affiliates (as such term is defined below) and third parties, such as customers,

collaborators, and partners;

WHEREAS, as a condition of the Employment Agreement,

Employee has agreed to the terms and conditions hereof and has agreed to enter into this Agreement.

NOW, THEREFORE, in consideration for

the Company’s execution of the Employment Agreement and to provide Employee with Confidential Information (as such term is defined

below), as well as other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties hereto, intending

to be legally bound, hereby agree as follows:

1. Scope.

Any references in this Agreement regarding Employee’s

duties and obligations to the Company (including, but not limited to, obligations related to confidentiality, work product, non-solicitation

and noncompetition) include Employee’s obligation to the Company’s affiliated entities, which includes the Company’s

parent and subsidiary corporations and business entities, if any, and any corporation or other business entity owned or controlled by

the Company or under common ownership or control with the Company (each an “Affiliate” and collectively, the “Affiliates”).

Employee also understands that if he is assigned to perform any work or duties with or for the Affiliates, this Agreement shall apply.

The word “cessation” in this Agreement refers to the ending of Employee’s employment with the Company.

2. Protection

of Confidential Information.

(a) “Confidential

Information” means information disclosed to Employee or known by Employee (including information conceived, originated, discovered,

or developed in whole or in part by Employee), about the Company and/or the Company’s business, products, processes, and services,

including but not limited to information relating to research, development, data, experimental work, innovations, ideas, improvements,

concepts, inventions, computer programs, designs, engineering data, formulas, systems, intellectual property, sketches, blueprints, flow

charts, technology, routines, algorithms, source and object codes, know-how, products and services under development, pricing and pricing

strategies, business plans, marketing and selling strategies, servicing, purchasing, accounting, engineering, cost and costing strategies,

sources of supply, information about customers and/or suppliers, information related to contracts, customer lists, customer requirements,

techniques, business methods or practices, operations, financial information, business forecasts, information related to computer hardware,

software, operating systems or the like, training and training programs, prospective business opportunities, and any other information

the Company is under an obligation to keep confidential. The parties agree that the following shall not be considered Confidential Information

subject to this Agreement: (i) information which prior to the time of disclosure by Company is in the public domain; (ii) information

that, after disclosure by Company, becomes part of the public domain by publication or otherwise, provided that such publication is not

in violation of this Agreement or any other confidentiality agreement; or (iii) information Employee is compelled to disclose by a court

or other tribunal of competent jurisdiction, provided however, that in such case Employee shall immediately give notice to the Company

to enable the Company to exercise its legal rights to prevent and/or limit such disclosure. In any event, Employee shall disclose only

that portion of the Confidential Information that, in the opinion of the Company’s legal counsel, is legally required to be disclosed

and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said

court or tribunal.

(b) Employee

acknowledges that all Confidential Information is, and for all times after the cessation of Employee’s employment shall remain,

the property of the Company. Employee agrees that he shall not directly or indirectly use, disseminate or disclose any Confidential Information

without having first obtained prior written permission from the Company, and to obtain such prior written permission whether during Employee’s

employment or after termination of such employment, except as shall be necessary in the ordinary course of performing his duties as an

employee of the Company in accordance with the Employment Agreement.

shall comply with any additional policies, rules and procedures established by the Company from time to time for the protection of any

Confidential Information.

3. Ownership

and Intellectual Property.

Employee agrees that all Confidential Information

that results from work performed by Employee for the Company shall be the sole and exclusive property of the Company or its nominees,

including without limitation any and all Confidential Information that comprises an invention or discovery by Employee, or an invention

or discovery to which Employee has made a contribution, and whether or not any such invention or discovery is patentable (“Inventions”).

Employee will and hereby does assign to the Company all of Employee’s rights in and to each and every Invention upon its creation,

including without limitation (a) patents, patent applications, and patent rights throughout the world; (b) rights associated with

works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask

work applications and mask work registrations; (c) rights relating to the protection of trade secrets and confidential information

throughout the world; (d) rights analogous to those set forth herein and any other proprietary rights relating to intangible property;

and (e) divisions, continuations, renewals, reissues and extensions of the foregoing (as applicable) now existing or hereafter filed,

issued or acquired (collectively, “IP Rights”). The Company and its nominees shall have the right to use and/or to apply for

statutory or common law protections for such Inventions in any and all countries. Employee further agrees (i) to assist the Company

in every proper way to obtain and from time to time to enforce such IP Rights relating to Inventions, and (ii) to execute and deliver

to the Company or its nominee upon request all such documents as the Company or its nominee may determine are necessary or appropriate,

including without limitation assignments of inventions. Such documents may be necessary to: (a) vest in the Company or its nominee

clear and marketable title in and to Inventions, (b) apply for, prosecute and obtain patents, copyrights, mask works rights and other

rights and protections relating to Inventions, or (c) enforce patents, copyrights, mask works rights and other rights and protections

relating to Inventions. Employee’s obligations pursuant to this Section shall continue beyond the termination of Employee’s

services for the Company, but the Company agrees to compensate Employee after the termination of such services at a reasonable rate for

time actually spent or expenses incurred by Employee at the Company’s request.

4. Conflicts.

Employee represents and warrants that his employment

or engagement by the Company and the execution and delivery of this Agreement and compliance with all the terms of this Agreement do not

and will not breach any written or oral agreement Employee has entered into relating to intellectual property, noncompetition or otherwise.

Employee shall not enter into any written or oral agreement in conflict with this Agreement. Moreover, without limiting the generality

of the provisions of the Employment Agreement requiring him to devote full-time efforts to his duties under such Employment Agreement,

during the period of Employee’s employment by the Company, Employee shall not, without the Company’s prior written consent,

directly or indirectly, engage in any employment, consulting or activity (other than Employee’s employment with the Company) relating

to any line of business in which the Company is now engaged, is engaged at such time or is considering, expects or plans to be engaged

or which would otherwise conflict with his employment obligations to the Company. Further, Employee shall abide by any policy concerning

conflicts of interest that the Company may from time to time have in effect.

In keeping with Employee’s fiduciary duties

to the Company, Employee agrees that while employed by the Company he shall not, acting alone or in conjunction with others, directly

or indirectly, become involved in a conflict of interest or, upon discovery thereof, allow such a conflict to continue. Moreover, Employee

agrees that he shall immediately disclose to the Company any facts which might involve any reasonable possibility of a conflict of interest.

It is agreed that any direct or indirect interest, connection with, or benefit from any outside activities, where such interest might

in any way adversely affect the Company, involves a possible conflict of interest. Circumstances in which a conflict of interest on the

part of Employee might arise, and which must be reported immediately by Employee to the Company, include, but are not limited to, the

following:

● ownership

of a material interest in any supplier, contractor, subcontractor, customer, or other entity

with which the Company does business;

● acting

in any capacity, including director, officer, partner, consultant, employee, distributor,

agent, or the like for a supplier, contractor, subcontractor, customer, or other entity with

which the Company does business;

● accepting,

directly or indirectly, payment, service, or loans from a supplier, contractor, subcontractor,

customer, or other entity with which the Employee does business, including, but not limited

to, gifts, trips, entertainment, or other favors of more than a nominal value;

● misuse

of the Company’s information or facilities to which Employee has access in a manner

that will be detrimental to the Employee’s interest, such as utilization for Employee’s

own benefit of know-how, inventions, or information developed through the Employee’s

business activities;

● disclosure

or other misuse of information of any kind obtained through Employee’s connection with

the Company;

● appropriation

by Employee or the diversion to others, directly or indirectly, of any business opportunity

in which it is known or could reasonably be anticipated that the Company would be interested;

and

● the

ownership, directly or indirectly, of a material interest in an enterprise in competition

with the Company, or acting as an owner, director, principal, officer, partner, consultant,

employee, agent, servant, or otherwise of any enterprise which is in competition with the

Company.

5. Non-Solicitation

of Customers and Suppliers. During the period of Employee’s employment with the Company and for twelve (12) months after

cessation of his employment with the Company (the “Non-Solicit Period”), Employee shall not, directly or indirectly, alone

or as a founder, partner, officer, director, employee, consultant, joint venturer, lender, stockholder or investor of any entity, divert

or attempt to divert any person, concern or entity, which is furnished services by or furnishes services to the Company, from doing business

with the Company or otherwise to change its relationship with the Company, or induce or attempt to induce any customer or supplier of,

or joint venturer with, the Company to cease being a customer or supplier of, or joint venturer with, the Company or otherwise to change

its relationship with the Company.

6. Non-Solicitation

and Non-Hire of Employees. During Employee’s employment with the Company and for twelve (12) months after cessation of his

employment with the Company, Employee shall not, directly or indirectly, alone or as a founder, partner, officer, director, employee,

consultant, joint venturer, lender, stockholder or investor of any entity, solicit or induce any employee or consultant of the Company

to leave his or her service with the Company, or assist in any manner in the recruitment or hiring of any such person.

7. Non-Disparagement.

Employee, the Board and the Company agree not, at any time, whether during or after cessation of Employee’s employment with the

Company, to make or publish any statement (orally or in writing) that libels, slanders, disparages or otherwise defaces the goodwill or

reputation (whether or not such disparagement legally constitutes libel or slander) of the Company or the Employee (or any of its Affiliates,

or its other officers, managers, directors, partners or investment professionals).

8. Competitive

Protection. Employee fully understands and realizes that the confidentiality, assignment and non-solicitation, and other terms

and conditions of this Agreement shall bind and obligate Employee as described in this Agreement.

9. Return

of Materials. All documents and other tangible objects containing or representing Confidential Information and all copies thereof

which are in the possession of Employee shall be and remain the property of Company and shall be promptly returned to Company or destroyed

by Employee upon the Employee’s termination and/or upon Company’s request.

10. Severability.

Each Section and the subparts of each Section herein shall be treated as separate and independent clauses, and the unenforceability of

any one clause shall in no way impair the enforceability of any of the other clauses of this Agreement. Moreover, if one or more of the

clauses contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so

as to be unenforceable at law, such clause or clauses shall be construed by the appropriate judicial body by limiting or reducing it or

them, so as to be coextensive with the maximum restrictions enforceable by the applicable law as it shall then appear. The language of

all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either

of the parties.

11. Survival.

All obligations, duties, rights, remedies, express representations or other provisions required to give force and effect to this Agreement,

or made in or given in this Agreement, which have accrued prior to cessation of Employee’s employment with the Company, shall survive

the cessation of Employee’s employment with the Company and shall continue and remain in full force and effect in accordance with

their respective terms, except where limited to the duration expressly stated therein.

12. Binding

Agreement; Entire Agreement; Assignment. This Agreement shall be binding upon and inure to the benefit of and be enforceable by

the respective successors, heirs (in the case of the Employee) and assigns of the parties hereto. This Agreement, along with the Employment

Agreement and the schedules thereto between the Company and Employee expresses the entire agreement between the Company and Employee with

respect to the subject matter hereof and supersedes any and all prior agreements, letters of intent and understandings between the parties,

and any and all promises, statements, and representations made by either party to the other concerning the subject matter hereof and the

terms applicable hereto, except for any existing confidentiality agreement between the parties. No rights or obligations of Employee under

this Agreement may be assigned or transferred by Employee without the prior written consent of the Company, and any attempted assignment

without such consent shall be null and void.

13. Governing

Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to

the principles of conflict of laws thereof.

14. Notices.

Any notice a party is required or may desire to give pursuant to this Agreement shall be given in writing in accordance with the requirements

of Section 9 of the Employment Agreement.

15. Waiver.

Except as set forth herein, no delay or omission to exercise any right, power or remedy accruing to any party shall impair any such right,

power or remedy or shall be construed to be a waiver of or an acquiescence to any breach hereof. No waiver by either party of any breach

by the other party of any condition or provision contained in this Agreement to be performed by such other party shall be deemed a waiver

of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed

by Employee and the Company.

16. Gender,

Etc. Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other

number, singular or plural, and any other gender, masculine, feminine or neuter, as the context indicates is appropriate.

17. Amendments

and Modifications. This Agreement may not be amended or modified other than by an agreement in writing signed by both of the parties.

18. Headings.

The headings of the sections of this Agreement are used for convenience only and shall not be deemed to constitute a part or to affect

the meaning of this Agreement.

IN WITNESS WHEREOF, the parties

hereto have executed this Non-Disclosure, Non-Solicitation and Intellectual Property Assignment Agreement as of the date first written

above.

EMPLOYEE

NIKI BIOSOLUTIONS, INC.

Thomas Freeburg

Ian Huen: Title: Chief Executive Officer

EXHIBIT B

The Employee shall receive the following equity awards

on the Commencement Date, pursuant to and governed by the Niki BioSolutions 2026 Equity Incentive Plan (the “Plan”), subject

to the Employee’s continued employment except as otherwise provided in the Employment Agreement:

Options to purchase 50,000 Company common shares,

with an exercise price of $8.83 per share, vesting in accordance with the following schedule:

(1) 15,000 Options vest upon the filing of the first full Annual

Report post-merger.

(2) 20,000 Options vesting Quarterly over the 8 Quarters following

the Commencement Date.

(3) 15,000 Options vest upon the Company raising a total aggregate

of $5,000,000 in cumulative Capital Investments.

Subject to any terms set forth in the Company’s

2026 Stock Incentive Plan or any successor thereto, 25,000 additional Options shall be granted upon the Commencement Date with the exercise

price of $8.83 and, along with any unvested Options, these 25,000 Options shall vest in full upon the occurrence of a Change in Control

(as hereinafter defined). For purposes of vesting, “Change in Control” shall mean the sale of all or substantially all of

the capital stock (other than the issuance by the Company of capital stock to one or more venture capitalists or other institutional investors

pursuant to an equity financing (including a debt financing that is convertible into equity) of the Company approved by a majority of

the Board of Directors of the Company, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other

than a transaction in which all or substantially all of the individuals and entities who were beneficial owners of the capital stock of

the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities

entitled to vote generally in the election of directors of the resulting, surviving or acquiring corporation in such transaction).

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 13, 2026

Entity Addresses [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 13, 2026

Entity File Number

001-38764

Entity Registrant Name

Niki

BioSolutions, Inc.

Entity Central Index Key

0001734005

Entity Tax Identification Number

42-3265309

Entity Incorporation, State or Country Code

Entity Address, Address Line One

116

Village Boulevard

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

609

Local Phone Number

951-2222

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

NIKI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Former Address [Member]

Entity Addresses [Line Items]

Entity Address, Address Line One

Hanover Square

Entity Address, City or Town

London

Entity Address, Country

Entity Address, Postal Zip Code

W1S 1BN

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressesLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: